Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 10/20 | 0.57 |
| ▸ | RAB9A | P51151 | 10/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747583 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| Acetic Acid SCHEMBL21519394 | 0.93 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL19449620 | 0.88 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL7747084 | 0.87 | MEN1 (0.58) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL7747086 | 0.87 | MEN1 (0.58) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL30423425 | 0.87 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL31058805 | 0.87 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17560906 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL1206598 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL1206597 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | claimed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | ALDH1A1 1048/4885MEN1 4058/4885KMT2A 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.